A cell-based combination product for the repair of large bone defects

Regenerative cell-based implants using periosteum-derived stem cells were developed for the treatment of large 3 cm fresh and 4.5 centimeter biological compromised bone gaps in a tibial sheep model and compared with an acellular ceramic-collagen void filler. It was hypothesized that the latter is in...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:BONE 2020-09, Vol.138
Hauptverfasser: Lammens, Johan, Marechal, Marina, Delport, Hendrik, Geris, Liesbet, Oppermann, Hermann, Vukicevic, Slobodan, Luyten, Frank P
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title BONE
container_volume 138
creator Lammens, Johan
Marechal, Marina
Delport, Hendrik
Geris, Liesbet
Oppermann, Hermann
Vukicevic, Slobodan
Luyten, Frank P
description Regenerative cell-based implants using periosteum-derived stem cells were developed for the treatment of large 3 cm fresh and 4.5 centimeter biological compromised bone gaps in a tibial sheep model and compared with an acellular ceramic-collagen void filler. It was hypothesized that the latter is insufficient to heal large skeletal defects due to reduced endogenous biological potency. To this purpose a comparison was made between the ceramic dicalciumphosphate scaffold (CopiOs®) as such, the same ceramic coated with clinical grade Bone Morphogenetic Protein 2 and 6 (BMP) only or a BMP coated cell-seeded combination product. These implants were evaluated in 2 sheep models, a fresh 3 cm critical size tibial defect and a 4.5 cm biologically exhausted tibial defect. For the groups in which growth factors were applied, BMP-6 was chosen at a dose of 344 μg for 3 cm and 1.500 μg or 3.800 μg for 4.5 cm defects. An additional group in the 4.5 cm defect was tested using BMP-2 in a dose of 1.500 μg. For all the cell based implants autologous periosteum-derived cells were used which were cultured in monolayer during 6 weeks. For the fresh defect 408 million cells and for the biologically exhausted tibial defect 612 million cells were drop-seeded on the BMP coated scaffolds. Bone healing was studied during 16 weeks postimplantation, using standard radiographs. While fresh defects responded to all treatments, regardless the use of cells, the biologically hampered defects responded in half of the cases and only if the BMP-cell combination product was used, supporting the concept that cell-based therapies may become attractive in treating defects with a compromised biological status.
format Article
fullrecord <record><control><sourceid>kuleuven</sourceid><recordid>TN_cdi_kuleuven_dspace_123456789_657525</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>123456789_657525</sourcerecordid><originalsourceid>FETCH-kuleuven_dspace_123456789_6575253</originalsourceid><addsrcrecordid>eNqVyj0OwiAYAFAGTaw_d_g2B9OkBSntaEyNB3BvKHxoFaEBajy-iwfQ6S1vRrJa8CpntKYLsozxXhQFa0SZkfYACq3NexlRg_LPfnAyDd7BGLyeVALjA6QbQsBRDgG8ASvDFaH3DkGjQZXimsyNtBE3X1dke2ovx3P-mCxOL3SdjqNU2JWU7Xkl6qaruOCUs3_m7rfZpXdiHz82SHs</addsrcrecordid><sourcetype>Institutional Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>A cell-based combination product for the repair of large bone defects</title><source>Lirias (KU Leuven Association)</source><source>Elsevier ScienceDirect Journals</source><creator>Lammens, Johan ; Marechal, Marina ; Delport, Hendrik ; Geris, Liesbet ; Oppermann, Hermann ; Vukicevic, Slobodan ; Luyten, Frank P</creator><creatorcontrib>Lammens, Johan ; Marechal, Marina ; Delport, Hendrik ; Geris, Liesbet ; Oppermann, Hermann ; Vukicevic, Slobodan ; Luyten, Frank P</creatorcontrib><description>Regenerative cell-based implants using periosteum-derived stem cells were developed for the treatment of large 3 cm fresh and 4.5 centimeter biological compromised bone gaps in a tibial sheep model and compared with an acellular ceramic-collagen void filler. It was hypothesized that the latter is insufficient to heal large skeletal defects due to reduced endogenous biological potency. To this purpose a comparison was made between the ceramic dicalciumphosphate scaffold (CopiOs®) as such, the same ceramic coated with clinical grade Bone Morphogenetic Protein 2 and 6 (BMP) only or a BMP coated cell-seeded combination product. These implants were evaluated in 2 sheep models, a fresh 3 cm critical size tibial defect and a 4.5 cm biologically exhausted tibial defect. For the groups in which growth factors were applied, BMP-6 was chosen at a dose of 344 μg for 3 cm and 1.500 μg or 3.800 μg for 4.5 cm defects. An additional group in the 4.5 cm defect was tested using BMP-2 in a dose of 1.500 μg. For all the cell based implants autologous periosteum-derived cells were used which were cultured in monolayer during 6 weeks. For the fresh defect 408 million cells and for the biologically exhausted tibial defect 612 million cells were drop-seeded on the BMP coated scaffolds. Bone healing was studied during 16 weeks postimplantation, using standard radiographs. While fresh defects responded to all treatments, regardless the use of cells, the biologically hampered defects responded in half of the cases and only if the BMP-cell combination product was used, supporting the concept that cell-based therapies may become attractive in treating defects with a compromised biological status.</description><identifier>ISSN: 8756-3282</identifier><language>eng</language><publisher>ELSEVIER SCIENCE INC</publisher><ispartof>BONE, 2020-09, Vol.138</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,315,776,780,27837</link.rule.ids></links><search><creatorcontrib>Lammens, Johan</creatorcontrib><creatorcontrib>Marechal, Marina</creatorcontrib><creatorcontrib>Delport, Hendrik</creatorcontrib><creatorcontrib>Geris, Liesbet</creatorcontrib><creatorcontrib>Oppermann, Hermann</creatorcontrib><creatorcontrib>Vukicevic, Slobodan</creatorcontrib><creatorcontrib>Luyten, Frank P</creatorcontrib><title>A cell-based combination product for the repair of large bone defects</title><title>BONE</title><description>Regenerative cell-based implants using periosteum-derived stem cells were developed for the treatment of large 3 cm fresh and 4.5 centimeter biological compromised bone gaps in a tibial sheep model and compared with an acellular ceramic-collagen void filler. It was hypothesized that the latter is insufficient to heal large skeletal defects due to reduced endogenous biological potency. To this purpose a comparison was made between the ceramic dicalciumphosphate scaffold (CopiOs®) as such, the same ceramic coated with clinical grade Bone Morphogenetic Protein 2 and 6 (BMP) only or a BMP coated cell-seeded combination product. These implants were evaluated in 2 sheep models, a fresh 3 cm critical size tibial defect and a 4.5 cm biologically exhausted tibial defect. For the groups in which growth factors were applied, BMP-6 was chosen at a dose of 344 μg for 3 cm and 1.500 μg or 3.800 μg for 4.5 cm defects. An additional group in the 4.5 cm defect was tested using BMP-2 in a dose of 1.500 μg. For all the cell based implants autologous periosteum-derived cells were used which were cultured in monolayer during 6 weeks. For the fresh defect 408 million cells and for the biologically exhausted tibial defect 612 million cells were drop-seeded on the BMP coated scaffolds. Bone healing was studied during 16 weeks postimplantation, using standard radiographs. While fresh defects responded to all treatments, regardless the use of cells, the biologically hampered defects responded in half of the cases and only if the BMP-cell combination product was used, supporting the concept that cell-based therapies may become attractive in treating defects with a compromised biological status.</description><issn>8756-3282</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>FZOIL</sourceid><recordid>eNqVyj0OwiAYAFAGTaw_d_g2B9OkBSntaEyNB3BvKHxoFaEBajy-iwfQ6S1vRrJa8CpntKYLsozxXhQFa0SZkfYACq3NexlRg_LPfnAyDd7BGLyeVALjA6QbQsBRDgG8ASvDFaH3DkGjQZXimsyNtBE3X1dke2ovx3P-mCxOL3SdjqNU2JWU7Xkl6qaruOCUs3_m7rfZpXdiHz82SHs</recordid><startdate>202009</startdate><enddate>202009</enddate><creator>Lammens, Johan</creator><creator>Marechal, Marina</creator><creator>Delport, Hendrik</creator><creator>Geris, Liesbet</creator><creator>Oppermann, Hermann</creator><creator>Vukicevic, Slobodan</creator><creator>Luyten, Frank P</creator><general>ELSEVIER SCIENCE INC</general><scope>FZOIL</scope></search><sort><creationdate>202009</creationdate><title>A cell-based combination product for the repair of large bone defects</title><author>Lammens, Johan ; Marechal, Marina ; Delport, Hendrik ; Geris, Liesbet ; Oppermann, Hermann ; Vukicevic, Slobodan ; Luyten, Frank P</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-kuleuven_dspace_123456789_6575253</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lammens, Johan</creatorcontrib><creatorcontrib>Marechal, Marina</creatorcontrib><creatorcontrib>Delport, Hendrik</creatorcontrib><creatorcontrib>Geris, Liesbet</creatorcontrib><creatorcontrib>Oppermann, Hermann</creatorcontrib><creatorcontrib>Vukicevic, Slobodan</creatorcontrib><creatorcontrib>Luyten, Frank P</creatorcontrib><collection>Lirias (KU Leuven Association)</collection><jtitle>BONE</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lammens, Johan</au><au>Marechal, Marina</au><au>Delport, Hendrik</au><au>Geris, Liesbet</au><au>Oppermann, Hermann</au><au>Vukicevic, Slobodan</au><au>Luyten, Frank P</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A cell-based combination product for the repair of large bone defects</atitle><jtitle>BONE</jtitle><date>2020-09</date><risdate>2020</risdate><volume>138</volume><issn>8756-3282</issn><abstract>Regenerative cell-based implants using periosteum-derived stem cells were developed for the treatment of large 3 cm fresh and 4.5 centimeter biological compromised bone gaps in a tibial sheep model and compared with an acellular ceramic-collagen void filler. It was hypothesized that the latter is insufficient to heal large skeletal defects due to reduced endogenous biological potency. To this purpose a comparison was made between the ceramic dicalciumphosphate scaffold (CopiOs®) as such, the same ceramic coated with clinical grade Bone Morphogenetic Protein 2 and 6 (BMP) only or a BMP coated cell-seeded combination product. These implants were evaluated in 2 sheep models, a fresh 3 cm critical size tibial defect and a 4.5 cm biologically exhausted tibial defect. For the groups in which growth factors were applied, BMP-6 was chosen at a dose of 344 μg for 3 cm and 1.500 μg or 3.800 μg for 4.5 cm defects. An additional group in the 4.5 cm defect was tested using BMP-2 in a dose of 1.500 μg. For all the cell based implants autologous periosteum-derived cells were used which were cultured in monolayer during 6 weeks. For the fresh defect 408 million cells and for the biologically exhausted tibial defect 612 million cells were drop-seeded on the BMP coated scaffolds. Bone healing was studied during 16 weeks postimplantation, using standard radiographs. While fresh defects responded to all treatments, regardless the use of cells, the biologically hampered defects responded in half of the cases and only if the BMP-cell combination product was used, supporting the concept that cell-based therapies may become attractive in treating defects with a compromised biological status.</abstract><pub>ELSEVIER SCIENCE INC</pub></addata></record>
fulltext fulltext
identifier ISSN: 8756-3282
ispartof BONE, 2020-09, Vol.138
issn 8756-3282
language eng
recordid cdi_kuleuven_dspace_123456789_657525
source Lirias (KU Leuven Association); Elsevier ScienceDirect Journals
title A cell-based combination product for the repair of large bone defects
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T21%3A19%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-kuleuven&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20cell-based%20combination%20product%20for%20the%20repair%20of%20large%20bone%20defects&rft.jtitle=BONE&rft.au=Lammens,%20Johan&rft.date=2020-09&rft.volume=138&rft.issn=8756-3282&rft_id=info:doi/&rft_dat=%3Ckuleuven%3E123456789_657525%3C/kuleuven%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true